SRNE - Sorrento gets EUA approval and import license for COVI-STIX test in Mexico

Sorrento Therapeutics ([[SRNE]] +5.8%) announces that it has received EUA approval and import license from Mexico authority for COVI-STIX (COVID-19 Virus Rapid Antigen Detection Test).The company also said that it is establishing a local "Sorrento Mexico Ltd" subsidiary to manage commercial operations in the country.COVI-STIX is a sensitive and rapid (about 15-minute) diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal or nasopharyngeal samples of patients.Sorrento will commercially launch the COVI-STIX test in Mexico with the first shipments expected to be delivered in July.The company had announced that the health regulatory authority for Mexico listed COVI-STIX on its official government website list of rapid antigen tests approved for emergency use in the country, earlier this month.

For further details see:

Sorrento gets EUA approval and import license for COVI-STIX test in Mexico